Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1989-06-06
1991-07-02
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 31195
Patent
active
050286226
ABSTRACT:
A treatment and composition for preventing in mammals the progressive exacerbation of symptoms associated with neurodegenerative disorders characterized by abnormal glutamate metabolism, elevated levels of peripheral glutamate or altered glutamate receptor characteristics. The treatment is comprised of the administration of compositions comprised of amino acids that are effective in retarding the development of symptoms associated with neurodegenerative disorders, presumably by activating the enzyme glutamate dehydrogenase. In the preferred embodiment, the branched chain amino acids L-leucine, L-isoleucine, and L-valine are disclosed as effective therapeutic agents for the treatment of amyotrophic lateral sclerosis.
REFERENCES:
patent: 4438144 (1984-03-01), Blackburn
A. Plaitakis and J. T. Caroscio, "Abnormal Glutmate Metabolism in Amyotrophic Lateral Sclerosis", Ann. Neurol., 22, pp. 575-579 (1987).
R. Tandan and W. G. Bradley, "Amyotrophic Lateral Sclerosis: Part 2, Etiopathogenesis", Ann. Neurol. 18, pp. 419-431 (1985).
P. S. Spencer et al., "Guam Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Linked to a Plant Excitant Neurotoxin", Science, 237, pp. 517-522 (1987).
A. Plaitakis et al., "Neurological Disorders Associated with Deficiency of Glutamate Dehydrogenase", Ann. Neurol. 15, pp. 144-153 (1984).
A. Plaitakis et al., "Abnormal Glutamate Metabolism in an Adult-Onset Degenerative Neurological Disorder", Science, 216, pp. 193-196 (1982).
A. Plaitakis et al., "The Treatment of GDH-Deficient Olivopantocerbellar Atrophy with Branched Chain Amino Acids", Neurology, 33 (Suppl. 2), p. 78 (1983).
J. W. Olney et al., "Cytotoxic Effects of Acidic and Sulphur Containing Amino Acids on the Infant Mouse Central Nervous System", Exp. Brain Res., 14, pp. 61-76 (1971).
R. Schwarcz et al., "Current Topics II Excitotoxic Models for Neurodegenerative Disorders", Life Sciences, 35, pp. 19-32 (1984).
B. Engelsen, "Neurotransmitter Glutamate: Its Clinical Importance", Acta Neurol. Scand. 74, pp. 337-355 (1986).
S. S. Stewart and S. H. Appel, "The Treatment of Amyotrophic Lateral Sclerosis", in Current Neurology Yearbook Publishers, Inc., 7, pp. 51-90 (1987).
S. M. Ross et al., "Specific Antagonism of Excitotoxic Action of Uncommon Amino Acids Assayed in Organotypic Mouse Cortical Cultures", Brain Research, 425, pp. 120-127 (1987).
K. L. Yielding and G. M. Tomkins, "An Effect of L-Leucine and Other Essential Amino Acids on the Structure and Activity of Glutamic Dehydrogenase", Proc. Natl. Acad. Sci. USA, 47, 983-989 (1961).
A. Senner and W. J. Malaisse, "The Stimulus-Secretion Coupling of Amino Acid-Induced Insulin Release. Insulinotropic Action of Branched Chain Amino Acids at Physiological Concentrations of Glucose and Glutamine", European J. of Clin. Invest, 11, pp. 455-460 (1981).
A. Senner et al., "The Stimulus-Secretion Coupling of Amino Acid-Induced Insulin Release XI. Kinetics of Deamination and Transamination Reactions", Horm. Metabol. Res., 14, pp. 405-409 (1982).
T. I. Rao et al., "Studies on Metabolism of Branched Chain Amino Acids in Brain and Other Tissues of Rat With Special Reference to Leucine", J. of Neurosci. Res. 7, pp. 387-395 (1982).
J. E. Fischer et al., "Plasma Amino Acids in Patients with Hepatic Encephalopathy: Effects of Amino Acid Infusions", Amer. J. of Surg., 127, pp. 40-47 (1974).
Rote Liste, No. 56 086, Edito Cantor, Aulendorf/Wurtt; Lactostrict Spezial Unlisted Drugs, vol. 37, No. 5, May 1985, Chatham, New Jersey, U.S.; "Illevasorb".
V, Iob et al., "Altered Clearance of Free Amino Acids from Plasma of Patients with Cirrhosis of the Liver", J. of Surg. Res., 6, pp. 233-239 (1966).
B. M. Patten and L. M. Klein, "L-Threonine and the Modification of ALS", Neurology, 35 (Suppl 1), p. 354 (1988).
R. Schwarcz and B. Meldrum, "Excitatory Aminoacid Antagonists Provide a Therapeutic Approach to Neurological Disorders", Lancet, 8447, pp. 140-143 (1985).
Ajinomoto Company, Inc.
Friedman Stanley J.
LandOfFree
Administration of amino acids as treatment for neurodegenerative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of amino acids as treatment for neurodegenerative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of amino acids as treatment for neurodegenerative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1247534